Glycomic Therapeutics Market Forecast to 2028

Report Code : TIPRE00029576 | Region : Global | Industry : Pharmaceuticals | Published Date : 22/Aug/2022
Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]

The global glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.

The report highlights prevailing trends and factors driving the market growth.

The demand for glycomic therapeutics is attributed to a wide application of glycan-based drugs followed by the development of new treatment processes, increasing research and development in the field of glycomic therapeutics, and rising usage of glycomics-based therapeutics in various diseases leading to the development of new treatment processes.

Wide Application to Treat Various Diseases Followed by Development of New Treatment Processes

Glycan-based therapeutics have wide applications in the pharmaceutical industry; the products are available in different structures & forms and developed as per the application. It is designed for various diseases, such as thrombosis, anemia, cancer, influenza, cataract, and antiinflammation.

The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used across the globeand are part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. Due to its known neuroprotective effects, EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models.

The largest and fastest-growing glycomic application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in research institutions. For instance, In April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule in cancer cells. The protein might revolutionize the area associated with cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative encourages research institutes to dive into establishing cutting-edge technologies, methods, and platforms that expedite drug discovery and development. Merck, a CQDM member, is financing the studies. The University of Alberta and 48HD will work together on the CQDM Quantum Leap initiative project. Additionally, GlycoNet—a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, provides the funds to enhance Canadians' quality of life.

•

• In December 2021, researchers at Griffith University’s Institute for Glycomics received US$ 2.6 million in funding from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. This has boosted their fight against cancer.

• In January 2022, the National Health and Medical Research Council (NHMRC) gave researchers from the Institute of Glycomics grants of more than US$ 1.1 million to help them create new medicines to treat multidrug-resistant gonorrhea infections.

• In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing preclinical outcomes.

Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). Further, the administration of microbiome-mediating glycans could radically improve the treatment of IBD sufferers who do not respond to the current standard of care and other patients who have autoimmune and inflammatory conditions by 16%.

These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for various diseases is driving the glycomic therapeutics market.

Based on class, the glycomic therapeutics market is bifurcated into isolated and synthetic. Based on structures, the glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglcans, glycophosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. Based on indication, the glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anemia, anti-adhesive & anti-inflammatory, cataract, Gaucher’s diseases, MPS-1 & IV, cancer, Alzheimer’s disease, influenza type A & B, and others. Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others.

 

Impact of COVID-19 Pandemic on Glycomic Therapeutics Market

The overall impact of the COVID-19 pandemic on the European glycomic therapeutics market was mixed, and the market regained traction and is expected to grow in the coming years. Pharmaceutical and biotechnology companies invested a huge amount in producing several pipeline products that can effectively combat the spread of SARS-CoV-2.

The onset of the COVID-19 pandemic positively impacted the glycomic therapeutics market. Pharmaceutical and biotechnology companies invested a huge amount in producing several pipeline products that can effectively combat the spread of SARS-CoV-2. Moreover, during the pandemic, the demand for the development of new drugs and vaccines increased to tackle COVID-19 in patients suffering from several other diseases. The increased number of researches led to high utilization of technology instead of human resource to prevent the spread of SARS-CoV-2. Furthermore, governments of Asia Pacific countries organized programs and open challenge events for researchers to develop innovative drugs for the treatment of COVID-19. Such events increased the overall number of research on COVID-19 owing to increased government funding.

. Thus, the above-mentioned factors indicate the overall positive impact on the glycomic therapeutics market during the forecast period.

Although elective surgeries resumed in the UK and many other countries in mid-2020, most hospitals were functioning at considerably reduced capacity, which translates to an ever-growing waitlist. As of September 2020, ~140,000 patients in England alone had been waiting more than a year for their surgeries—100 times the number in 2019. And with a new, highly transmissible variant of SARS-CoV-2 circulating in the UK that has resulted in a third national lockdown and further appointment cancellations, patients are now facing longer waits. Further, according to the National Library of Medicine, the decline in COVID-19 cases after the third wave of the COVID-19 pandemic grew to 51% for ophthalmic procedures, 68% for pain procedures, and 49% for orthopedic procedures. The number of electoral processes conducted increased in the EU but was still below pre-pandemic standards. In contrast, during the COVID-19 pandemic, a generic trend toward reduced numbers of nonelective, emergency neurosurgical cases in countries such as Austria, Switzerland, and the Czech Republic was observed. This was majorly driven by a decreased incidence of conditions commonly associated with traumatic aetiologies, including brain injuries, spine conditions, and chronic subdural hematomas. Despite the challenges of delivering health services and intensive care during the COVID-19 pandemic, data indicated that emergency care could still be provided in these countries.

Various organic and inorganic strategies are adopted by companies operating in the global glycomic therapeutics market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few significant developments by key players operating in the global glycomic therapeutics market are listed below.

• In May 2022, Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc., with an aim to create specialty products.

• In March 2022, Halozyme Therapeutics announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gave exclusive access to Halozyme's ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target.

A few major primary and secondary sources that were considered while preparing the report on the global glycomic therapeutics market are the American Medical Association, the British Journal of Surgery, and the National Library of Medicine.

List of 10 Companies:

1. Intellihep Ltd

2. Protalix Biotherapeutics

3. BioMarin Pharmaceutical Inc.

4. Genzyme Corporation (Sanofi)

5. Halozyme Therapeutics, Inc.

6. Bayer AG

7. Alzheon, Inc.

8. GlycoMar

9. GlaxoSmithKline plc.

10. F. Hoffmann-La Roche Ltd

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Glycomic Therapeutics Market – By Class

1.3.2 Global Glycomic Therapeutics Market – By Structures

1.3.3 Global Glycomic Therapeutics Market – By Indications

1.3.4 Global Glycomic Therapeutics Market – By Mode of Action

1.3.5 Global Glycomic Therapeutics Market – By Geography

2. Glycomic Therapeutics Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Glycomic Therapeutics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America – PEST Analysis

4.2.2 Europe – PEST Analysis

4.2.3 Asia Pacific – PEST Analysis

4.2.4 Middle East & Africa – PEST Analysis

4.2.5 South & Central America – PEST Analysis

4.3 Expert Opinion

5. Glycomic Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes

5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics

5.2 Market Restraints

5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.

5.3 Market Opportunities

5.3.1 Wide Applications of Glycomics in Therapeutics

5.4 Future Trends

5.4.1 New Tools in Glycomics Research

5.5 Impact Analysis

6. Glycomic Therapeutics Market– Global Analysis

6.1 Global Glycomic Therapeutics Market Revenue Forecast and Analysis

6.1.1 Global Glycomic Therapeutics Market Revenue Forecast and Analysis

6.1.2 Global Glycomic Therapeutics Market – Market Potential Analysis, By Region

6.2 Company Analysis

6.2.1 Growth Strategy Analysis

6.2.2 Performance of Key Players

6.2.2.1 Genzyme Corporation (Sanofi)

6.2.2.2 GlaxoSmithKline plc.

6.3 Glycan-Based Drugs in Clinical Trial Phases

7. Global Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class

7.1 Overview

7.2 Global Glycomic Therapeutics Market, By Class 2022 & 2028 (%)

7.3 Isolated

7.3.1 Overview

7.3.2 Isolated Revenue and Forecast to 2028 (US$ Million)

7.4 Synthetic

7.4.1 Overview

7.4.2 Synthetic - Revenue and Forecast to 2028 (US$ Million)

8. Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication

8.1 Overview

8.2 Global Glycomics Market, By Indication 2022 & 2028 (%)

8.3 Thrombosis and Chemoprophylaxis

8.3.1 Overview

8.3.2 Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)

8.4 Anaemia

8.4.1 Overview

8.4.2 Anaemia Revenue and Forecast to 2028 (US$ Million)

8.5 Anti-adhesive and Anti-inflammatory

8.5.1 Overview

8.5.2 Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)

8.6 Cataract

8.6.1 Overview

8.6.2 Cataract Revenue and Forecast to 2028 (US$ Million)

8.7 Gaucher’s diseases

8.7.1 Overview

8.7.2 Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)

8.8 MPS-1 & IV

8.8.1 Overview

8.8.2 MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)

8.9 Cancer

8.9.1 Overview

8.9.2 Cancer Revenue and Forecast to 2028 (US$ Million)

8.10 Alzheimer's

8.10.1 Overview

8.10.2 Alzheimer's Revenue and Forecast to 2028 (US$ Million)

8.11 Influenza Type A and B

8.11.1 Overview

8.11.2 Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Others Revenue and Forecast to 2028 (US$ Million)

9. Global Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures

9.1 Overview

9.2 Global Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)

9.3 Glycoproteins

9.3.1 Overview

9.3.2 Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Targeting Sialic Acid

9.4.1 Overview

9.4.2 Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Zanamivir

9.4.3.1 Overview

9.4.3.2 Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.4.4 Oseltamivir

9.4.4.1 Overview

9.4.4.2 Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Proteoglycans

9.5.1 Overview

9.5.2 Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans

9.6.1 Overview

9.6.2 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7 Targeting Glycosaminoglycans

9.7.1 Overview

9.7.2 Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7.3 Heparin

9.7.3.1 Overview

9.7.3.2 Heparin - Market Revenue and Forecast to 2028 (US$ Million)

9.7.4 Hyaluronan (HA)

9.7.4.1 Overview

9.7.4.2 Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)

9.7.5 Laronidase

9.7.5.1 Overview

9.7.5.2 Laronidase - Market Revenue and Forecast to 2028 (US$ Million)

9.7.6 Galsulfase (Naglazyme)

9.7.6.1 Overview

9.7.6.2 Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.7 Hyaluronidase (Cumulase)

9.7.7.1 Overview

9.7.7.2 Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.8 Others

9.7.8.1 Overview

9.7.8.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

9.8 Targeting Glycosphingolipids

9.8.1 Overview

9.8.2 Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3 Imiglucerase (Cerezyme)

9.8.3.1 Overview

9.8.3.2 Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)

9.8.4 Agalsidase (Fabrazyme)

9.8.4.1 Overview

9.8.4.2 Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.5 N-butyl-deoxynojirimycin (DNJ)

9.8.5.1 Overview

9.8.5.2 N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.6 Others

9.8.6.1 Overview

9.8.6.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9 Others

9.9.1 Overview

9.9.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3 Acarbose

9.9.3.1 Overview

9.9.3.2 Acarbose - Market Revenue and Forecast to 2028 (US$ Million)

9.9.4 Alglucosidase Alfa (Myozyme)

9.9.4.1 Overview

9.9.4.2 Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.9.5 Allosamidin

9.9.5.1 Overview

9.9.5.2 Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)

9.9.6 Others

9.9.6.1 Overview

9.9.6.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

10. Global Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action

10.1 Overview

10.2 Global Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)

10.3 Inhibits Neuraminidase

10.3.1 Overview

10.3.2 Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)

10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate

10.4.1 Overview

10.4.2 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)

10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)

10.5.1 Overview

10.5.2 Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)

10.6 Tissue Plasminogen Activator

10.6.1 Overview

10.6.2 Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

10.7 Inhibits Glucosylceramide Synthase

10.7.1 Overview

10.7.2 Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

10.8 Interleukin 1 And 2 And 3

10.8.1 Overview

10.8.2 Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

10.9 Beta And Gamma Interferons

10.9.1 Overview

10.9.2 Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)

10.10 Others

10.10.1 Overview

10.10.2 Others- Market Revenue And Forecasts To 2028 (US$ Million)

11. Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Geographical Analysis

11.1 North America: Glycomic Therapeutics Market

11.1.1 Overview

11.1.2 North America: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3 North America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.4 North America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.4.1 North America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.4.2 North America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.4.3 North America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.4.4 North America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.5 North America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6 North America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.7 North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.1.8 US: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.8.1.1 Overview

11.1.8.1.2 US: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.8.1.3 US: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.8.1.4 US: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.8.1.4.1 US: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.8.1.4.2 US: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.8.1.4.3 US: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.8.1.4.4 US: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.8.1.5 US: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.8.1.6 US: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.8.2 Canada: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.8.2.1 Overview

11.1.8.2.2 Canada: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.8.2.3 Canada: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.8.2.4 Canada: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.8.2.4.1 Canada: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.8.2.4.2 Canada: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.8.2.4.3 Canada: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.8.2.4.4 Canada: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.8.2.5 Canada: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.8.2.6 Canada: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.8.3 Mexico: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.8.3.1 Overview

11.1.8.3.2 Mexico: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.8.3.3 Mexico: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.8.3.4 Mexico: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.8.3.4.1 Mexico: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.8.3.4.2 Mexico: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.8.3.4.3 Mexico: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.8.3.4.4 Mexico: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.8.3.5 Mexico: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.8.3.6 Mexico: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2 Europe: Glycomic Therapeutics Market

11.2.1 Overview

11.2.2 Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.3 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.4 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.4.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.4.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.2.4.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.2.4.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.5 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.6 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2.7 Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.2.7.1 Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.1.1 Overview

11.2.7.1.2 Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.1.3 Germany: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.7.1.4 Germany: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.7.1.4.1 Germany: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.7.1.4.2 Germany: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.2.7.1.4.3 Germany: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.2.7.1.4.4 Germany: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.7.1.5 Germany: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.7.1.6 Germany: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2.7.2 UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.2.1 Overview

11.2.7.2.2 UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.2.3 UK: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.7.2.4 UK: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.7.2.4.1 UK: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.7.2.4.2 UK: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.2.7.2.4.3 UK: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.2.7.2.4.4 UK: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.7.2.5 UK: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.7.2.6 UK: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2.7.3 France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.3.1 Overview

11.2.7.3.2 France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.3.3 France: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.7.3.4 France: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.7.3.4.1 France: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.7.3.4.2 France: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.2.7.3.4.3 France: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.2.7.3.4.4 France: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.7.3.5 France: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.7.3.6 France: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2.7.4 Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.4.1 Overview

11.2.7.4.2 Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.4.3 Italy: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.7.4.4 Italy: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.7.4.4.1 Italy: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.7.4.4.2 Italy: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.2.7.4.4.3 Italy: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.2.7.4.4.4 Italy: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.7.4.5 Italy: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.7.4.6 Italy: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2.7.5 Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.5.1 Overview

11.2.7.5.2 Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.5.3 Spain: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.7.5.4 Spain: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.7.5.4.1 Spain: Glycomic Therapeutics Market, by Targeting Glycosphingolipid, 2019-2028 (US$ Million)

11.2.7.5.4.2 Spain: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.7.5.4.3 Spain: Glycomic Therapeutics Market, by Targeting Glycosaminoglycans, 2019-2028 (US$ Million)

11.2.7.5.4.4 Spain: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.7.5.5 Spain: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.7.5.6 Spain: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.2.7.6 Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.6.1 Overview

11.2.7.6.2 Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.6.3 Rest of Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.2.7.6.4 Rest of Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.2.7.6.4.1 Rest of Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.2.7.6.4.2 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.2.7.6.4.3 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.2.7.6.4.4 Rest of Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.2.7.6.5 Rest of Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.2.7.6.6 Rest of Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.3 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts To 2028

11.3.1 Overview

11.3.2 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.4 Asia Pacific: Glycomic Therapeutics Market, by Structures, 2019–2028 (US$ Million)

11.3.4.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.4.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.4.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.4.4 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.5 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.6 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.3.7 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)

11.3.7.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.1.1 Overview

11.3.7.1.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.1.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.7.1.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.3.7.1.4.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.7.1.4.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.7.1.4.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.7.1.4.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.7.1.5 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.7.1.6 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.3.7.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.2.1 Overview

11.3.7.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.2.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.7.2.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.3.7.2.4.1 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.7.2.4.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.7.2.4.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.7.2.4.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.7.2.5 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.7.2.6 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.3.7.3 India Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.3.1 Overview

11.3.7.3.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.3.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.7.3.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.3.7.3.4.1 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.7.3.4.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.7.3.4.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.7.3.4.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.7.3.5 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.7.3.6 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.3.7.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.4.1 Overview

11.3.7.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.7.4.4 South Korea: Glycomic Therapeutics Market, by Structures, 2019–2028 (US$ Million)

11.3.7.4.4.1 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.7.4.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.7.4.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.7.4.4.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.7.4.5 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.7.4.6 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.3.7.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.5.1 Overview

11.3.7.5.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.3.7.5.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.7.5.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.3.7.5.4.1 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.7.5.4.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.7.5.4.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.7.5.4.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.7.5.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.7.5.6 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.3.7.6 Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.6.1 Overview

11.3.7.6.2 Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.6.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.3.7.6.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.3.7.6.4.1 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.3.7.6.4.2 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.3.7.6.4.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.3.7.6.4.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.3.7.6.5 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.3.7.6.6 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.4 Middle East & Africa: Glycomic Therapeutics Market

11.4.1 Overview

11.4.2 Middle East & Africa: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.4.3 Middle East & Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.4.4 Middle East & Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.4.4.1 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.4.4.2 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.4.4.3 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.4.4.4 Middle East & Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.4.5 Middle East & Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.4.6 Middle East & Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.4.7 Middle East & Africa: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.4.7.1 Saudi Arabia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.4.7.1.1 Overview

11.4.7.1.2 Saudi Arabia: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.1.3 Saudi Arabia: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.4.7.1.4 Saudi Arabia: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.4.7.1.4.1 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.4.7.1.4.2 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.4.7.1.4.3 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.4.7.1.4.4 Saudi Arabia: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.4.7.1.5 Saudi Arabia: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.4.7.1.6 Saudi Arabia: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.4.7.2 UAE: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.4.7.2.1 Overview

11.4.7.2.2 UAE: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.2.3 UAE: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.4.7.2.4 UAE: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.4.7.2.4.1 UAE: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.4.7.2.4.2 UAE: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.4.7.2.4.3 UAE: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.4.7.2.4.4 UAE: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.4.7.2.5 UAE: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.4.7.2.6 UAE: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.4.7.3 South Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.4.7.3.1 Overview

11.4.7.3.2 South Africa: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.3.3 South Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.4.7.3.4 South Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.4.7.3.4.1 South Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.4.7.3.4.2 South Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.4.7.3.4.3 South Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.4.7.3.4.4 South Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.4.7.3.5 South Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.4.7.3.6 South Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.4.7.4 Rest of Middle East and Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.4.7.4.1 Overview

11.4.7.4.2 Rest of MEA: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.4.3 Rest of MEA: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.4.7.4.4 Rest of MEA: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.4.7.4.4.1 Rest of MEA: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.4.7.4.4.2 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.4.7.4.4.3 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.4.7.4.4.4 Rest of MEA: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.4.7.4.5 Rest of MEA: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.4.7.4.6 Rest of MEA: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.5 South & Central America: Glycomic Therapeutics Market

11.5.1 Overview

11.5.2 South & Central America: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.5.3 South & Central America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.5.4 South & Central America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.5.4.1 South & Central America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.5.4.2 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.5.4.3 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.5.4.4 South & Central America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.5.5 South & Central America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.5.6 South & Central America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.5.7 South & Central America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.5.7.1 Brazil: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.5.7.1.1 Brazil: Glycomic Therapeutics Market – Revenue and Forec

LIST OF TABLES.

Table 1. North America Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 3. North America Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 4. North America Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 5. North America Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 6. North America Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 7. North America Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 8. North America Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 9. US Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (USD Million)

Table 10. US Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 11. US Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 12. US Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 13. US Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 14. US Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (USD Million)

Table 15. US Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 16. US Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 17. Canada Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (USD Million)

Table 18. Canada Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 19. Canada Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 20. Canada Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 21. Canada Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 22. Canada Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (USD Million)

Table 23. Canada Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 24. Canada Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 25. Mexico Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 26. Mexico Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 27. Mexico Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 28. Mexico Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 29. Mexico Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 30. Mexico Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 31. Mexico Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 32. Mexico Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 33. Europe Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 34. Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 35. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 36. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 37. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 38. Europe Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 39. Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 40. Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 41. Germany Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 42. Germany Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 43. Germany Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 44. Germany Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 45. Germany Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 46. Germany Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 47. Germany Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 48. Germany Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 49. UK Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 50. UK Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 51. UK Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 52. UK Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 53. UK Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 54. UK Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 55. UK Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 56. UK Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 57. France Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 58. France Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 59. France Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 60. France Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 61. France Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 62. France Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 63. France Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 64. France Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 65. Italy Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 66. Italy Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 67. Italy Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 68. Italy Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 69. Italy Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 70. Italy Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 71. Italy Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 72. Italy Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 73. Spain Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 74. Spain Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 75. Spain Glycomic Therapeutics Market, by Targeting Glycosphingolipid – Revenue and Forecast to 2028 (US$ Million)

Table 76. Spain Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 77. Spain Glycomic Therapeutics Market, by Targeting Glycosaminoglycans – Revenue and Forecast to 2028 (US$ Million)

Table 78. Spain Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 79. Spain Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 80. Spain Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 81. Rest of Europe Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 82. Rest of Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 83. Rest of Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 84. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 85. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 86. Rest of Europe Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 87. Rest of Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 88. Rest of Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 89. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 90. Asia Pacific: Glycomic Therapeutics Market, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 91. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 92. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 93. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 94. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 95. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 96. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 97. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 98. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 99. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 100. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 101. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 102. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 103. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 104. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 105. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 106. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 107. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 108. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 109. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 110. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 111. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 112. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 113. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 114. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 115. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 116. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 117. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 118. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 119. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 120. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 121. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 122. South Korea: Glycomic Therapeutics Market, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 123. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 124. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 125. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 126. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 127. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 128. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 129. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 130. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 131. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 132. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 133. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 134. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 135. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 136. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 137. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 138. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 139. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 140. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 141. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 142. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 143. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 144. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 145. Middle East & Africa Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 146. Middle East & Africa Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 147. Middle East & Africa Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 148. Middle East & Africa Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 149. Middle East & Africa Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 150. Middle East & Africa Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 151. Middle East & Africa Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 152. Middle East & Africa Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 153. Saudi Arabia Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 154. Saudi Arabia Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 155. Saudi Arabia Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 156. Saudi Arabia Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 157. Saudi Arabia Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 158. Saudi Arabia Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 159. Saudi Arabia Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 160. Saudi Arabia Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 161. UAE Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 162. UAE Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 163. UAE Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 164. UAE Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 165. UAE Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 166. UAE Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 167. UAE Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 168. UAE Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 169. South Africa Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 170. South Africa Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 171. South Africa Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 172. South Africa Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 173. South Africa Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 174. South Africa Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 175. South Africa Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 176. South Africa Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 177. Rest of MEA Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 178. Rest of MEA Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 179. Rest of MEA Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 180. Rest of MEA Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 181. Rest of MEA Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 182. Rest of MEA Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 183. Rest of MEA Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 184. Rest of MEA Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 185. South & Central America Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 186. South & Central America Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 187. South & Central America Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 188. South & Central America Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 189. South & Central America Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 190. South & Central America Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 191. South & Central America Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 192. South & Central America Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 193. Brazil Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 194. Brazil Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 195. Brazil Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 196. Brazil Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 197. Brazil Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 198. Brazil Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 199. Brazil Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 200. Brazil Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 201. Argentina Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 202. Argentina Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 203. Argentina Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 204. Argentina Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 205. Argentina Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 206. Argentina Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 207. Argentina Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 208. Argentina Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 209. Rest of SCAM Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 210. Rest of SCAM Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 211. Rest of SCAM Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 212. Rest of SCAM Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 213. Rest of SCAM Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 214. Rest of SCAM Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 215. Rest of SCAM Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 216. Rest of SCAM Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 217. Organic Developments in the Glycomic Therapeutics Market

Table 218. Inorganic Developments in the Glycomic Therapeutics Market

Table 219. Glossary of Terms in Glycomic Therapeutics Market

List of 10 Companies:

1. Intellihep Ltd

2. Protalix Biotherapeutics

3. BioMarin Pharmaceutical Inc.

4. Genzyme Corporation (Sanofi)

5. Halozyme Therapeutics, Inc.

6. Bayer AG

7. Alzheon, Inc.

8. GlycoMar

9. GlaxoSmithKline plc.

10. F. Hoffmann-La Roche Ltd

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the glycomic therapeutics market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in the glycomic therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhancing the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Glycomic Therapeutics Market Forecast to 2028 )
  • Single User Price $4,550$3,640
  • Site Price $6,550$5,240
  • Enterprise Price $8,550$6,840
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry